Amniotic fluid stem cells as a novel strategy for the treatment of fetal and neonatal neurological diseases

Even in the context of modern medicine, infants with fetal and neonatal neurological diseases such as cerebral palsy and myelomeningocele suffer serious long-lasting impairment due to the irreversible neuronal damage. The promotion of neurologically intact survival in patients with perinatal intract...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Placenta (Eastbourne) 2021-01, Vol.104, p.247-252
Hauptverfasser: Abe, Yushi, Ochiai, Daigo, Sato, Yu, Otani, Toshimitsu, Fukutake, Marie, Ikenoue, Satoru, Kasuga, Yoshifumi, Tanaka, Mamoru
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 252
container_issue
container_start_page 247
container_title Placenta (Eastbourne)
container_volume 104
creator Abe, Yushi
Ochiai, Daigo
Sato, Yu
Otani, Toshimitsu
Fukutake, Marie
Ikenoue, Satoru
Kasuga, Yoshifumi
Tanaka, Mamoru
description Even in the context of modern medicine, infants with fetal and neonatal neurological diseases such as cerebral palsy and myelomeningocele suffer serious long-lasting impairment due to the irreversible neuronal damage. The promotion of neurologically intact survival in patients with perinatal intractable neurological diseases requires the development of novel strategies. One promising strategy involves the use of human amniotic fluid stem cells (hAFSCs), which have attracted much attention in recent years and are known to exert anti-inflammatory and neuroprotective effects. In recent years, the therapeutic effects of hAFSCs on fetal-neonatal neurological diseases have become evident as per intense research efforts by our group and others. Specifically, hAFSCs administered into the nasal cavity migrated to the brain and controlled local inflammation in a rodent model of neonatal hypoxic-ischemic encephalopathy. In contrast, hAFSCs administered intraperitoneally did not migrate to the brain; they rather formed spheroids in the abdominal cavity, resulting in the suppression of systemic inflammation (including in the brain) via the secretion of anti-inflammatory cytokines in concert with peritoneal macrophages in a rodent model of periventricular leukomalacia. Moreover, studies in a rat model of myelomeningocele suggested that hAFSCs administered in utero secreted hepatocyte growth factor and protected the exposed spinal cord during pregnancy. Importantly, autologous hAFSCs, whose use for fetal-neonatal treatment does not raise ethical issues, can be collected during pregnancy and prepared in sufficient numbers for therapeutic use. This article outlines the results of preclinical research on fetal stem cell therapy, mainly involving hAFSCs, in the context of perinatal neurological diseases. •Human amniotic fluid stem cells (hAFSCs) are anti-inflammatory and neuroprotective.•HAFSCs, for perinatal neurological diseases.•HAFSCs can suppress neuronal inflammation and restore neuronal cells.
doi_str_mv 10.1016/j.placenta.2021.01.009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2479038426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0143400421000175</els_id><sourcerecordid>2479038426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-96e169105aad366a8fad3bdb5684da872e81a3679b30cf2599640e3308563ff43</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVJaZy0fyHomMs6o4-VV7eE0C8w9NKehSyNUjm7K0fSBvLvK-Ok18ALw4hn9M68hFwxWDNg6ma_PozW4VztmgNna2gC_YGsWC94JxjwM7ICJkUnAeQ5uShlD42QjH8i50JIxUDpFXm8m-aYanQ0jEv0tFScqMNxLNQ20Tk949hes6348EJDyrT-RVoz2jo1e5oCDVjtSO3s6YxptsdmxiWnMT1E1xofC9qC5TP5GOxY8MtrvSR_vn39ff-j2_76_vP-bts5KWTttEKmNIPeWi-UskNoded3vRqkt8OG48CsUBu9E-AC77VWElAIGHolQpDiklyf_j3k9LRgqWaK5XiTbfstxXC50SAGyVVD1Ql1OZWSMZhDjpPNL4aBOQZt9uYtaHMM2kAT6DZ49eqx7Cb0_8fekm3A7QnAdulzxGyKizg79DGjq8an-J7HP4nckvs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2479038426</pqid></control><display><type>article</type><title>Amniotic fluid stem cells as a novel strategy for the treatment of fetal and neonatal neurological diseases</title><source>Elsevier ScienceDirect Journals</source><creator>Abe, Yushi ; Ochiai, Daigo ; Sato, Yu ; Otani, Toshimitsu ; Fukutake, Marie ; Ikenoue, Satoru ; Kasuga, Yoshifumi ; Tanaka, Mamoru</creator><creatorcontrib>Abe, Yushi ; Ochiai, Daigo ; Sato, Yu ; Otani, Toshimitsu ; Fukutake, Marie ; Ikenoue, Satoru ; Kasuga, Yoshifumi ; Tanaka, Mamoru</creatorcontrib><description>Even in the context of modern medicine, infants with fetal and neonatal neurological diseases such as cerebral palsy and myelomeningocele suffer serious long-lasting impairment due to the irreversible neuronal damage. The promotion of neurologically intact survival in patients with perinatal intractable neurological diseases requires the development of novel strategies. One promising strategy involves the use of human amniotic fluid stem cells (hAFSCs), which have attracted much attention in recent years and are known to exert anti-inflammatory and neuroprotective effects. In recent years, the therapeutic effects of hAFSCs on fetal-neonatal neurological diseases have become evident as per intense research efforts by our group and others. Specifically, hAFSCs administered into the nasal cavity migrated to the brain and controlled local inflammation in a rodent model of neonatal hypoxic-ischemic encephalopathy. In contrast, hAFSCs administered intraperitoneally did not migrate to the brain; they rather formed spheroids in the abdominal cavity, resulting in the suppression of systemic inflammation (including in the brain) via the secretion of anti-inflammatory cytokines in concert with peritoneal macrophages in a rodent model of periventricular leukomalacia. Moreover, studies in a rat model of myelomeningocele suggested that hAFSCs administered in utero secreted hepatocyte growth factor and protected the exposed spinal cord during pregnancy. Importantly, autologous hAFSCs, whose use for fetal-neonatal treatment does not raise ethical issues, can be collected during pregnancy and prepared in sufficient numbers for therapeutic use. This article outlines the results of preclinical research on fetal stem cell therapy, mainly involving hAFSCs, in the context of perinatal neurological diseases. •Human amniotic fluid stem cells (hAFSCs) are anti-inflammatory and neuroprotective.•HAFSCs, for perinatal neurological diseases.•HAFSCs can suppress neuronal inflammation and restore neuronal cells.</description><identifier>ISSN: 0143-4004</identifier><identifier>EISSN: 1532-3102</identifier><identifier>DOI: 10.1016/j.placenta.2021.01.009</identifier><identifier>PMID: 33461069</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Amniotic fluid stem cells ; Cerebral palsy ; Hypoxic-ischemic encephalopathy ; Myelomeningocele ; Periventricular leukomalacia ; Regenerative medicine</subject><ispartof>Placenta (Eastbourne), 2021-01, Vol.104, p.247-252</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-96e169105aad366a8fad3bdb5684da872e81a3679b30cf2599640e3308563ff43</citedby><cites>FETCH-LOGICAL-c434t-96e169105aad366a8fad3bdb5684da872e81a3679b30cf2599640e3308563ff43</cites><orcidid>0000-0003-3652-5389</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.placenta.2021.01.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33461069$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abe, Yushi</creatorcontrib><creatorcontrib>Ochiai, Daigo</creatorcontrib><creatorcontrib>Sato, Yu</creatorcontrib><creatorcontrib>Otani, Toshimitsu</creatorcontrib><creatorcontrib>Fukutake, Marie</creatorcontrib><creatorcontrib>Ikenoue, Satoru</creatorcontrib><creatorcontrib>Kasuga, Yoshifumi</creatorcontrib><creatorcontrib>Tanaka, Mamoru</creatorcontrib><title>Amniotic fluid stem cells as a novel strategy for the treatment of fetal and neonatal neurological diseases</title><title>Placenta (Eastbourne)</title><addtitle>Placenta</addtitle><description>Even in the context of modern medicine, infants with fetal and neonatal neurological diseases such as cerebral palsy and myelomeningocele suffer serious long-lasting impairment due to the irreversible neuronal damage. The promotion of neurologically intact survival in patients with perinatal intractable neurological diseases requires the development of novel strategies. One promising strategy involves the use of human amniotic fluid stem cells (hAFSCs), which have attracted much attention in recent years and are known to exert anti-inflammatory and neuroprotective effects. In recent years, the therapeutic effects of hAFSCs on fetal-neonatal neurological diseases have become evident as per intense research efforts by our group and others. Specifically, hAFSCs administered into the nasal cavity migrated to the brain and controlled local inflammation in a rodent model of neonatal hypoxic-ischemic encephalopathy. In contrast, hAFSCs administered intraperitoneally did not migrate to the brain; they rather formed spheroids in the abdominal cavity, resulting in the suppression of systemic inflammation (including in the brain) via the secretion of anti-inflammatory cytokines in concert with peritoneal macrophages in a rodent model of periventricular leukomalacia. Moreover, studies in a rat model of myelomeningocele suggested that hAFSCs administered in utero secreted hepatocyte growth factor and protected the exposed spinal cord during pregnancy. Importantly, autologous hAFSCs, whose use for fetal-neonatal treatment does not raise ethical issues, can be collected during pregnancy and prepared in sufficient numbers for therapeutic use. This article outlines the results of preclinical research on fetal stem cell therapy, mainly involving hAFSCs, in the context of perinatal neurological diseases. •Human amniotic fluid stem cells (hAFSCs) are anti-inflammatory and neuroprotective.•HAFSCs, for perinatal neurological diseases.•HAFSCs can suppress neuronal inflammation and restore neuronal cells.</description><subject>Amniotic fluid stem cells</subject><subject>Cerebral palsy</subject><subject>Hypoxic-ischemic encephalopathy</subject><subject>Myelomeningocele</subject><subject>Periventricular leukomalacia</subject><subject>Regenerative medicine</subject><issn>0143-4004</issn><issn>1532-3102</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkE1rGzEQhkVJaZy0fyHomMs6o4-VV7eE0C8w9NKehSyNUjm7K0fSBvLvK-Ok18ALw4hn9M68hFwxWDNg6ma_PozW4VztmgNna2gC_YGsWC94JxjwM7ICJkUnAeQ5uShlD42QjH8i50JIxUDpFXm8m-aYanQ0jEv0tFScqMNxLNQ20Tk949hes6348EJDyrT-RVoz2jo1e5oCDVjtSO3s6YxptsdmxiWnMT1E1xofC9qC5TP5GOxY8MtrvSR_vn39ff-j2_76_vP-bts5KWTttEKmNIPeWi-UskNoded3vRqkt8OG48CsUBu9E-AC77VWElAIGHolQpDiklyf_j3k9LRgqWaK5XiTbfstxXC50SAGyVVD1Ql1OZWSMZhDjpPNL4aBOQZt9uYtaHMM2kAT6DZ49eqx7Cb0_8fekm3A7QnAdulzxGyKizg79DGjq8an-J7HP4nckvs</recordid><startdate>20210115</startdate><enddate>20210115</enddate><creator>Abe, Yushi</creator><creator>Ochiai, Daigo</creator><creator>Sato, Yu</creator><creator>Otani, Toshimitsu</creator><creator>Fukutake, Marie</creator><creator>Ikenoue, Satoru</creator><creator>Kasuga, Yoshifumi</creator><creator>Tanaka, Mamoru</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3652-5389</orcidid></search><sort><creationdate>20210115</creationdate><title>Amniotic fluid stem cells as a novel strategy for the treatment of fetal and neonatal neurological diseases</title><author>Abe, Yushi ; Ochiai, Daigo ; Sato, Yu ; Otani, Toshimitsu ; Fukutake, Marie ; Ikenoue, Satoru ; Kasuga, Yoshifumi ; Tanaka, Mamoru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-96e169105aad366a8fad3bdb5684da872e81a3679b30cf2599640e3308563ff43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Amniotic fluid stem cells</topic><topic>Cerebral palsy</topic><topic>Hypoxic-ischemic encephalopathy</topic><topic>Myelomeningocele</topic><topic>Periventricular leukomalacia</topic><topic>Regenerative medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abe, Yushi</creatorcontrib><creatorcontrib>Ochiai, Daigo</creatorcontrib><creatorcontrib>Sato, Yu</creatorcontrib><creatorcontrib>Otani, Toshimitsu</creatorcontrib><creatorcontrib>Fukutake, Marie</creatorcontrib><creatorcontrib>Ikenoue, Satoru</creatorcontrib><creatorcontrib>Kasuga, Yoshifumi</creatorcontrib><creatorcontrib>Tanaka, Mamoru</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Placenta (Eastbourne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abe, Yushi</au><au>Ochiai, Daigo</au><au>Sato, Yu</au><au>Otani, Toshimitsu</au><au>Fukutake, Marie</au><au>Ikenoue, Satoru</au><au>Kasuga, Yoshifumi</au><au>Tanaka, Mamoru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amniotic fluid stem cells as a novel strategy for the treatment of fetal and neonatal neurological diseases</atitle><jtitle>Placenta (Eastbourne)</jtitle><addtitle>Placenta</addtitle><date>2021-01-15</date><risdate>2021</risdate><volume>104</volume><spage>247</spage><epage>252</epage><pages>247-252</pages><issn>0143-4004</issn><eissn>1532-3102</eissn><abstract>Even in the context of modern medicine, infants with fetal and neonatal neurological diseases such as cerebral palsy and myelomeningocele suffer serious long-lasting impairment due to the irreversible neuronal damage. The promotion of neurologically intact survival in patients with perinatal intractable neurological diseases requires the development of novel strategies. One promising strategy involves the use of human amniotic fluid stem cells (hAFSCs), which have attracted much attention in recent years and are known to exert anti-inflammatory and neuroprotective effects. In recent years, the therapeutic effects of hAFSCs on fetal-neonatal neurological diseases have become evident as per intense research efforts by our group and others. Specifically, hAFSCs administered into the nasal cavity migrated to the brain and controlled local inflammation in a rodent model of neonatal hypoxic-ischemic encephalopathy. In contrast, hAFSCs administered intraperitoneally did not migrate to the brain; they rather formed spheroids in the abdominal cavity, resulting in the suppression of systemic inflammation (including in the brain) via the secretion of anti-inflammatory cytokines in concert with peritoneal macrophages in a rodent model of periventricular leukomalacia. Moreover, studies in a rat model of myelomeningocele suggested that hAFSCs administered in utero secreted hepatocyte growth factor and protected the exposed spinal cord during pregnancy. Importantly, autologous hAFSCs, whose use for fetal-neonatal treatment does not raise ethical issues, can be collected during pregnancy and prepared in sufficient numbers for therapeutic use. This article outlines the results of preclinical research on fetal stem cell therapy, mainly involving hAFSCs, in the context of perinatal neurological diseases. •Human amniotic fluid stem cells (hAFSCs) are anti-inflammatory and neuroprotective.•HAFSCs, for perinatal neurological diseases.•HAFSCs can suppress neuronal inflammation and restore neuronal cells.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33461069</pmid><doi>10.1016/j.placenta.2021.01.009</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-3652-5389</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0143-4004
ispartof Placenta (Eastbourne), 2021-01, Vol.104, p.247-252
issn 0143-4004
1532-3102
language eng
recordid cdi_proquest_miscellaneous_2479038426
source Elsevier ScienceDirect Journals
subjects Amniotic fluid stem cells
Cerebral palsy
Hypoxic-ischemic encephalopathy
Myelomeningocele
Periventricular leukomalacia
Regenerative medicine
title Amniotic fluid stem cells as a novel strategy for the treatment of fetal and neonatal neurological diseases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A12%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amniotic%20fluid%20stem%20cells%20as%20a%20novel%20strategy%20for%20the%20treatment%20of%20fetal%20and%20neonatal%20neurological%20diseases&rft.jtitle=Placenta%20(Eastbourne)&rft.au=Abe,%20Yushi&rft.date=2021-01-15&rft.volume=104&rft.spage=247&rft.epage=252&rft.pages=247-252&rft.issn=0143-4004&rft.eissn=1532-3102&rft_id=info:doi/10.1016/j.placenta.2021.01.009&rft_dat=%3Cproquest_cross%3E2479038426%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2479038426&rft_id=info:pmid/33461069&rft_els_id=S0143400421000175&rfr_iscdi=true